Sangamo Therapeutics, Inc. SGMO Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sangamo Therapeutics, Inc. SGMO

SGMO 0.590

+3.6%

Oct 31 9:30 AM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: PLegee	2/6/2011 1:22:19 PM
	of 368

Felt the stock did well after announcing earnings and more importantly, their $60.6M cash position. Many tech and biotech stocks seem to be getting hit harder than usual this reporting season if quarterly estimates were not notably exceeded; Sangamo prevailed nicely. Some decent support in the low $7s; probably test that range a couple of times prior to the CROI presentation in early March. Stock should move big one way or another after CROI presentation. Ed Lanphier seems to be very excited about the interim trial updates to be presented; even practically hinting of success during the last conference call. Remember, however, he was also excited two years ago about the SB509 initial results that analysts interpreted otherwise and sent the stock plunging. I think he is wiser from that experience and this time it will be different, we shall see. With good clinical news we obviously go higher and take out the $8.50 resistance; status quo results or overt cheerleading with no significant progress made, will send the stock down sharply. Still, even if successful, we are years away from commercial production of any drugs and many hurdles remain in our way. Nonetheless, the possibilities that this platform currently implies could be game changing in medical advancement; actual cures for major genetic disorders. CROI will be very insightful into the potential or broken promises of this technology. Other companies and consortiums have entered this field, a testament to the potential of this science. SGMO has several years head start on the competition and locked down patented IP; they are the force to be reckoned with. Maybe the heightened awareness of the medical community will make Ed a bit more considerate in future partnership discussions. A secondary certainly looms for this company in 2011 (assuming no partnership), hopefully it does not get issued by Jefferies this time who profited on shorting of the stock they helped issue (their underwriting restrictions terminated 90 days after issuance). The secondary offering (conjecture by analysts following the stock; nothing announced as of yet by company) should offer a good opportunity to purchase additional positions in the stock post CROI.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next